New Launch9 Jun 2026, 01:32 pm
Wanbury Ltd Launches New APIs, Expands Market Reach
AI Summary
Wanbury Limited has announced the expansion of its regulatory submissions for new Active Pharmaceutical Ingredients (APIs). The company has submitted Drug Master Files (DMFs) for Diphenhydramine HCl to Malaysia and Singapore, and plans to explore new markets for Paroxetine HCl in Korea and Latin America. Additionally, Wanbury received a zero-observation audit report from MFDS (Korea FDA) for its Patalganga facility following an inspection in April 2026, indicating strong compliance and readiness for international markets.
Key Highlights
- New API submissions in Malaysia and Singapore for Diphenhydramine HCl.
- Plans to enter Korean and Latin American markets with Paroxetine HCl.
- Patalganga facility receives zero observations from Korea FDA audit.
- Strengthens global regulatory compliance and market access.
Price Impact
More from WANBURY